Hypha Labs to build commercial-scale mushroom accelerator

Published 29/09/2025, 11:06
Hypha Labs to build commercial-scale mushroom accelerator

LAS VEGAS - Hypha Labs, Inc. (OTCQB:FUNI), a micro-cap biotechnology company currently valued at $3.85 million and trading below its InvestingPro Fair Value, has entered an agreement with Automated Technical Services to design and build a commercial-scale Mushroom Accelerator, the company announced Monday.

The new system will produce Hypha’s proprietary mushroom-based ingredients for sale to nutraceutical manufacturers globally, scaling up from the company’s current countertop units that compress the production of functional mushroom compounds from months to eight days.

The collaboration aims to expand Hypha’s production capabilities to serve the functional mushroom market, which the company states is valued at $33 billion globally and projected to reach $49 billion by 2028. According to InvestingPro analysis, the company faces significant financial challenges with a weak financial health score of 1.42 and a current ratio of 0.16, indicating potential liquidity concerns.

Under the agreement, ATS will work with Hypha’s R&D team to adapt the company’s proprietary processes to a commercial production environment, enabling supply to nutraceutical brands and supplement manufacturers.

"This agreement is a major step in taking our Mushroom Accelerator technology from the kitchen counter to industrial production," said Craig Ellins, Chief Scientific Officer of Hypha Labs, in the press release statement.

Hypha Labs is currently conducting a Regulation A+ public offering for investors interested in the company’s expansion from consumer devices to large-scale ingredient production.

The company describes its technology as a method for producing active ingredients found in functional mushrooms using patent-pending mushroom accelerators.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.